vs
波士顿科学（BSX）与Eversource Energy（ES）财务数据对比。点击上方公司名可切换其他公司
波士顿科学的季度营收约是Eversource Energy的1.5倍（$5.2B vs $3.4B），波士顿科学净利率更高（25.7% vs 12.6%，领先13.2%），Eversource Energy同比增速更快（13.4% vs 11.6%），过去两年波士顿科学的营收复合增速更高（12.4% vs 0.6%）
波士顿科学是一家美国跨国生物科技与生物医学工程企业，专注于介入医学领域医疗设备的研发生产，产品覆盖介入心内科、介入放射科、神经调控、肿瘤、泌尿、妇科、内镜、心脏及血管外科等多个专科诊疗场景。
Eversource Energy是位列财富500强的上市能源企业，总部位于美国马萨诸塞州斯普林菲尔德，在康涅狄格州哈特福德、马萨诸塞州波士顿均设有办公据点，旗下多家受监管子公司为康涅狄格、马萨诸塞、新罕布什尔三州约400万用户提供零售电力、天然气及供水服务。
BSX vs ES — 直观对比
营收规模更大
BSX
是对方的1.5倍
$3.4B
营收增速更快
ES
高出1.8%
11.6%
净利率更高
BSX
高出13.2%
12.6%
两年增速更快
BSX
近两年复合增速
0.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $3.4B |
| 净利润 | $1.3B | $423.2M |
| 毛利率 | 69.5% | — |
| 营业利润率 | — | 21.1% |
| 净利率 | 25.7% | 12.6% |
| 营收同比 | 11.6% | 13.4% |
| 净利润同比 | 99.0% | 468.8% |
| 每股收益（稀释后） | $0.90 | $1.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSXES
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | $3.4B | ||
| Q3 25 | $5.1B | $3.2B | ||
| Q2 25 | $5.1B | $2.8B | ||
| Q1 25 | $4.7B | $4.1B | ||
| Q4 24 | $4.6B | $3.0B | ||
| Q3 24 | $4.2B | $3.1B | ||
| Q2 24 | $4.1B | $2.5B |
净利润BSXES
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | $423.2M | ||
| Q3 25 | $755.0M | $369.4M | ||
| Q2 25 | $795.0M | $354.6M | ||
| Q1 25 | $672.0M | $552.7M | ||
| Q4 24 | $563.0M | $74.4M | ||
| Q3 24 | $468.0M | $-116.2M | ||
| Q2 24 | $322.0M | $337.2M |
毛利率BSXES
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | 67.7% | — | ||
| Q1 25 | 68.8% | — | ||
| Q4 24 | 67.8% | — | ||
| Q3 24 | 68.8% | — | ||
| Q2 24 | 69.2% | — |
营业利润率BSXES
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 21.1% | ||
| Q3 25 | 20.7% | 21.4% | ||
| Q2 25 | 16.2% | 23.4% | ||
| Q1 25 | 19.8% | 22.5% | ||
| Q4 24 | 14.8% | 11.7% | ||
| Q3 24 | 17.4% | 20.0% | ||
| Q2 24 | 12.6% | 23.8% |
净利率BSXES
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | 12.6% | ||
| Q3 25 | 14.9% | 11.5% | ||
| Q2 25 | 15.7% | 12.5% | ||
| Q1 25 | 14.4% | 13.4% | ||
| Q4 24 | 12.3% | 2.5% | ||
| Q3 24 | 11.1% | -3.8% | ||
| Q2 24 | 7.8% | 13.3% |
每股收益（稀释后）BSXES
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | $1.11 | ||
| Q3 25 | $0.51 | $0.99 | ||
| Q2 25 | $0.53 | $0.96 | ||
| Q1 25 | $0.45 | $1.50 | ||
| Q4 24 | $0.38 | $0.16 | ||
| Q3 24 | $0.32 | $-0.33 | ||
| Q2 24 | $0.22 | $0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $135.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $16.2B |
| 总资产 | — | $63.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BSXES
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $135.4M | ||
| Q3 25 | $1.3B | $259.3M | ||
| Q2 25 | $534.0M | $343.7M | ||
| Q1 25 | $725.0M | $111.4M | ||
| Q4 24 | $414.0M | $26.7M | ||
| Q3 24 | $2.5B | $97.9M | ||
| Q2 24 | $2.9B | — |
总债务BSXES
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | — | ||
| Q3 25 | $11.1B | — | ||
| Q2 25 | $11.1B | — | ||
| Q1 25 | $10.5B | — | ||
| Q4 24 | $9.0B | — | ||
| Q3 24 | $9.2B | — | ||
| Q2 24 | $9.0B | — |
股东权益BSXES
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | $16.2B | ||
| Q3 25 | $23.4B | $16.0B | ||
| Q2 25 | $22.4B | $15.7B | ||
| Q1 25 | $22.2B | $15.3B | ||
| Q4 24 | $21.8B | $15.0B | ||
| Q3 24 | $20.7B | $15.0B | ||
| Q2 24 | $20.4B | $14.8B |
总资产BSXES
| Q1 26 | — | — | ||
| Q4 25 | $43.7B | $63.8B | ||
| Q3 25 | $42.7B | $61.7B | ||
| Q2 25 | $41.6B | $61.0B | ||
| Q1 25 | $40.1B | $60.2B | ||
| Q4 24 | $39.4B | $59.6B | ||
| Q3 24 | $38.1B | $58.6B | ||
| Q2 24 | $37.1B | $58.4B |
负债/权益比BSXES
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $916.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-67.3M |
| 自由现金流率自由现金流/营收 | — | -2.0% |
| 资本支出强度资本支出/营收 | — | 29.2% |
| 现金转化率经营现金流/净利润 | — | 2.16× |
| 过去12个月自由现金流最近4个季度 | — | $-45.1M |
8季度趋势，按日历期对齐
经营现金流BSXES
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $916.1M | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $541.0M | $1.0B | ||
| Q4 24 | $1.5B | $642.1M | ||
| Q3 24 | $1.0B | $555.6M | ||
| Q2 24 | $813.0M | $670.7M |
自由现金流BSXES
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $-67.3M | ||
| Q3 25 | $1.2B | $-26.3M | ||
| Q2 25 | $1.1B | $15.3M | ||
| Q1 25 | $354.0M | $33.2M | ||
| Q4 24 | $1.2B | $-546.5M | ||
| Q3 24 | $823.0M | $-515.4M | ||
| Q2 24 | $658.0M | $-400.8M |
自由现金流率BSXES
| Q1 26 | — | — | ||
| Q4 25 | 19.2% | -2.0% | ||
| Q3 25 | 22.9% | -0.8% | ||
| Q2 25 | 22.3% | 0.5% | ||
| Q1 25 | 7.6% | 0.8% | ||
| Q4 24 | 25.8% | -18.4% | ||
| Q3 24 | 19.6% | -16.8% | ||
| Q2 24 | 16.0% | -15.8% |
资本支出强度BSXES
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 29.2% | ||
| Q3 25 | 3.6% | 35.0% | ||
| Q2 25 | 3.1% | 36.7% | ||
| Q1 25 | 4.0% | 24.5% | ||
| Q4 24 | 6.1% | 40.0% | ||
| Q3 24 | 4.3% | 35.0% | ||
| Q2 24 | 3.8% | 42.3% |
现金转化率BSXES
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | 2.16× | ||
| Q3 25 | 1.78× | 2.98× | ||
| Q2 25 | 1.62× | 2.98× | ||
| Q1 25 | 0.81× | 1.88× | ||
| Q4 24 | 2.59× | 8.63× | ||
| Q3 24 | 2.14× | — | ||
| Q2 24 | 2.52× | 1.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
ES
| Residential | $1.2B | 35% |
| Commercial | $789.0M | 23% |
| Eversource Electric Transmission | $573.8M | 17% |
| Wholesale Transmission Revenue | $570.0M | 17% |
| Industrial | $102.6M | 3% |
| Water Distribution Segment | $58.4M | 2% |
| Eversource Water | $56.3M | 2% |
| Other Revenue Adjustmentsfrom Contractswith Customers | $25.9M | 1% |
